Odyral (Dorzolamide)

Dorzolamide, the active ingredient in Odyral, is a carbonic anhydrase inhibitor presented as a topical ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of various forms of glaucoma and ocular hypertension.

GNH USA supplies Odyral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide acts on the aqueous humor production pathway and is indicated for several pressure‑related eye conditions. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Secondary glaucoma (e.g., pseudoexfoliative): assists in controlling pressure when other therapies are insufficient.

Adverse reactions may occur with any ophthalmic carbonic anhydrase inhibitor.

Common Side Effects: - Burning or stinging sensation at the instillation site. - Transient blurred vision. - Taste disturbance (bitter taste). - Conjunctival hyperemia. - Mild ocular discomfort. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis). - Persistent corneal edema. - Significant visual acuity loss. - Iridocyclitis. - Stevens‑Johnson syndrome. - Toxic epidermal necrolysis.

Before using Dorzolamide‑containing eye drops, consider the following safety measures. - Allergy assessment: avoid if known hypersensitivity to dorzolamide or sulfonamides. - Ocular surgery: inform surgeon of use prior to any procedure. - Systemic sulfonamide use: monitor for cross‑reactivity. - Renal impairment: use with caution and under medical supervision. - Pregnancy and lactation: discuss risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide may interact with other medications affecting ocular pressure or systemic sulfonamide pathways.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive intra‑ocular pressure reduction. - Sulfonamide antibiotics (e.g., sulfamethoxazole): increased risk of hypersensitivity.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: potential for excessive pressure lowering. - Non‑steroidal anti‑inflammatory eye drops: may alter ocular surface tolerance. - Anticholinergic agents: possible reduction in tear production.